| Ytd | 30.49% | |
| 1y | 95.84% |
| Open | 12.81 | Prev Close | 12.81 | Low | 12.24 | High | 12.88 | Mkt Cap | 766.00M |
| Vol | 2.55M | Avg Vol | 732.90K | EPS | -1.18 | P/E | N/A | Forward P/E | -5.13 |
| Beta | 1.66 | Short Ratio | 19.61 | Inst. Own | 56.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 13.88 | 200-d Avg | 11.87 | 1yr Est | 7.00 |
DSGN News
U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after bea
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the anal
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvement
Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech s
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares
Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatment
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also
Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperfor
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the anal
Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the anal
Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a
Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market P
RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perfor
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Per
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the anal
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday
On Tuesday, 210 companies reached new 52-week lows.
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company
On Tuesday, 65 companies set new 52-week lows.
Monday's session saw 114 companies set new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here ar
On Friday, 497 companies set new 52-week lows.
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 r
Gainers
Gainers
On Wednesday, 807 companies reached new 52-week lows.